参考文献/References:
[1] American Thyroid Association(ATA)Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer,Cooper DS,Doherty G M,et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2009,19(11):1167-1214.
[2] Lin JD.Increased incidence of papillary thyroid microcarcinoma with decreased tumor size of thyroid cancer.Med Oncol,2010,27(2):510-518.
[3] Pazaitou-Panayiotou K,Capezzone M,Pacini F.Clinical features and therapeutic implication of papillary thyroid microcarcinoma.Thyroid,2007,17(11):1085-1092.
[4] Noguchi S,Yamashita H,Uchino S,et al.Papillary microcarcinoma.World JSurg,2008,32(5):747-753.
[5] Lin JD,Chao TC,HsueH C,et al.High recurrent rate of multicentric papillary thyroid carcinoma.Ann SurgOncol,2009,16(9):2609-2616.
[6] Lecumbem B,Alvarez-Escola C,Martln-Vaquero P,et al.Solitary hemorrhagic cerebellar metastasis from occult papillary thyroid microcarcinoma.Thyroid,2010,20(5):563-567.
[7] Koike K,Fujii T,Yanaga H,et al.Axillary lymph node recurrence of papillary thyroid microcarcinoma:report of a case.Surg Today,2004,34(5):440-443.
[8] Kim HY,Park W Y,Lee KE,et al.Comparative analysis of gene expression profiles of papillary thyroid microcarcinoma and papillary thyroid carcinoma.J Cancer Res Ther,2010,6(4):452-457.
[9] Samir AE,Vij A,Seale MK,et al.Ultrasound-guided percutaneous thyroid nodule core biopsy:clinical utility in patients with prior nondiagnostic fine-needle aspirate.Thyroid,2012,22(5):461-467.
[10] Yun M,Noh TW,Cho A,et al.Visually discernible[188 F] fluo-rodeoxyglucose uptake in papillary thyroid microcarcinoma:a potential new risk factor.J Clin Endocrinol Metab,2010,95(7):3182-3188.
[11] Moon HJ,Son E,Kim EK,et al.The diagnostic values of ultrasound and ultrasound-guided fine needle aspiration in subcentimetersized thyroid nodules.Ann Surg Oncol,2012,19(1):52-59.
[12] Hughes DT,Haymart MR,Miller BS,et al.The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years.Thyroid,2011,21(3):231-236.
[13] Zhang XQ,Xu YZ,Zhang YF,et al.Intraoperative detection of thyroid carcinoma by fourier transform infrared spectrometry.J Surg Res,2011,171(2):650-656.
[14] Yu XM,Wan Y,Sippel RS,et al.Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases.Ann Surg,2011,254(4):653-660.
[15] AroraN,Turbendian HK,Kato MA,et al.Papillary thyroid carcinoma and microcarcinoma:is there a need to distinguish the two?.Thyroid,2009,19(5):473-477.
[16] Niemeier LA,Kuffner Akatsu H,Song C,et al.A combined molecular-pathologic score improves risk stratification of thyroid papillary micFocarcinoma.Cancer,2012,118(8):2069-2077.
[17] Ito Y,Tomoda C,Uruno T,et al.Papillary microcarcinoma of the thyroid:how should it be treated?.World J Surg,2004,28(11):1115-1121.
[18] Minuto MN,Miccoli M,Viola D,et al.Incidental versus clinically evident thyroid cancer:A 5-year follow-up study[J/OL].Head Neck,2012[2012-07-25].http://onlinelibrary.wiley.com/doi/10.1002/hed.22974/pdf.[published online ahead of print].
[19] Bradly DP,Reddy V,Prinz RA,et al.Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases.Surgery,2009,146(6):1099-1104.
[20] Koh YW,Shah MH,Agarwal K,et al.Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.Endocr Relat Cancer,2012,19(1):29-38.
[21] Capdevila J,Igiesias L,Halperin I,et al.Sorafenib in metastatic thyroid cancer.Endocr Relat Cancer,2012,19(2):209-216.
[22] Creach KM,Siegel BA,Nussenbaum B,et al.Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma.ISRN Endocrinol,2012:816386.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]张晖,段清,卓娜,等.经直肠超声引导下“6+X”点法前列腺穿刺活检诊断前列腺癌的临床价值分析[J].国际放射医学核医学杂志,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
Zhang Hui,Duan Qing,Zhuo Na,et al.Meta-analysis of the diagnostic value of transrectal ultrasound-guided “6+X” points biopsy in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
[8]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[9]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[10]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]